SplitJul 14, 2026, 09:31 AM
Genprex Announces 1-for-22 Reverse Stock Split
AI Summary
Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026. This action will convert every 22 shares into one, with fractional shares rounded up, resulting in an estimated 504,936 shares outstanding post-split from 11,108,577 shares. The company also provided an investor presentation with business updates on its oncology and diabetes gene therapy programs, including ongoing enrollment in Phase 2a of the Acclaim-1 clinical trial.
Key Highlights
- Genprex announced a one-for-twenty-two (1:22) reverse stock split.
- The reverse stock split will be effective at 12:01 a.m. ET on July 16, 2026.
- Common Stock will begin trading on a split-adjusted basis on July 16, 2026.
- Every 22 shares of common stock will convert into one (1) share.
- Fractional shares will be rounded up to the next whole share.
- Estimated 504,936 shares outstanding post-split from 11,108,577 shares.
- The CUSIP number will change, but the trading symbol GNPX will remain.
- Investor presentation provides updates on oncology and diabetes gene therapy programs.
- Currently enrolling patients in Phase 2a of the Acclaim-1 clinical trial.
Price Impact
More from GNPX